BridgeBio Pharma, Inc.
BBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.35 | -0.57 | 0.10 | -0.53 |
| FCF Yield | -10.22% | -8.05% | -37.89% | -22.68% |
| EV / EBITDA | -14.09 | -14.03 | -6.22 | -7.01 |
| Quality | ||||
| ROIC | -76.78% | -149.35% | -100.64% | -64.97% |
| Gross Margin | 98.25% | 73.71% | 95.58% | 95.53% |
| Cash Conversion Ratio | 0.96 | 0.82 | 0.87 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 41.91% | -48.90% | 111.14% | 19.79% |
| Free Cash Flow Growth | 1.39% | -24.24% | 22.04% | -34.12% |
| Safety | ||||
| Net Debt / EBITDA | -2.40 | -2.41 | -3.39 | -2.50 |
| Interest Coverage | -5.97 | -7.47 | -6.37 | -12.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -897.49 | -1,521.27 | -1,148.22 | -1,289.56 |